Oramed Pharmaceuticals (NASDAQ:ORMP) Share Price Passes Below 200 Day Moving Average – Time to Sell?

Shares of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) passed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $2.36 and traded as low as $2.36. Oramed Pharmaceuticals shares last traded at $2.37, with a volume of 43,141 shares traded.

Wall Street Analyst Weigh In

Separately, StockNews.com lowered Oramed Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, February 19th.

Oramed Pharmaceuticals Price Performance

The stock has a market cap of $95.54 million, a PE ratio of 21.55 and a beta of 1.61. The business has a 50 day moving average price of $2.30 and a two-hundred day moving average price of $2.36.

Institutional Trading of Oramed Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the stock. Boothbay Fund Management LLC boosted its stake in shares of Oramed Pharmaceuticals by 2.0% during the fourth quarter. Boothbay Fund Management LLC now owns 845,188 shares of the biotechnology company’s stock valued at $2,045,000 after purchasing an additional 16,857 shares during the period. Dimensional Fund Advisors LP lifted its position in Oramed Pharmaceuticals by 143.8% during the fourth quarter. Dimensional Fund Advisors LP now owns 118,995 shares of the biotechnology company’s stock valued at $288,000 after buying an additional 70,190 shares during the period. BML Capital Management LLC lifted its position in Oramed Pharmaceuticals by 20.9% during the fourth quarter. BML Capital Management LLC now owns 2,643,907 shares of the biotechnology company’s stock valued at $6,398,000 after buying an additional 457,716 shares during the period. World Equity Group Inc. purchased a new position in Oramed Pharmaceuticals during the fourth quarter valued at $48,000. Finally, Peapod Lane Capital LLC purchased a new position in shares of Oramed Pharmaceuticals in the 4th quarter worth about $550,000. Hedge funds and other institutional investors own 12.73% of the company’s stock.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.